Improving bio-availability of the expensive oral oncolytic drug abiraterone by food intake - SNACK

Radboud Universitair Medisch Centrum0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•-Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow-up.;->= 18 year old men who use abiraterone ;-Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. ;-Feasible to collect blood samples from

•Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product ;•Malabsorption syndrome.;•Major resection of the stomach or small bowel.;•Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject*s safety, provision of informed consent, or compliance to study procedures. ;•Unable or unwilling to discontinue use of prohibited medications listed in for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of day 1 and for the duration of the study.;•Concurrent use of other substances known or likely to interfere with the pharmacokinetics of abiraterone

发起方